HK1210779A1 - Inhibitors of brutons tyrosine kinase - Google Patents

Inhibitors of brutons tyrosine kinase

Info

Publication number
HK1210779A1
HK1210779A1 HK15111588.8A HK15111588A HK1210779A1 HK 1210779 A1 HK1210779 A1 HK 1210779A1 HK 15111588 A HK15111588 A HK 15111588A HK 1210779 A1 HK1210779 A1 HK 1210779A1
Authority
HK
Hong Kong
Prior art keywords
inhibitors
tyrosine kinase
brutons tyrosine
brutons
kinase
Prior art date
Application number
HK15111588.8A
Other languages
English (en)
Chinese (zh)
Inventor
Niala Bhagirath
Romyr Dominique
Joshua Kennedy-Smith
Francisco Javier Lopez-Tapia
Eric Mertz
Qi Qiao
Sung-Sau So
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1210779A1 publication Critical patent/HK1210779A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK15111588.8A 2012-10-26 2015-11-25 Inhibitors of brutons tyrosine kinase HK1210779A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261718746P 2012-10-26 2012-10-26
US201361831443P 2013-06-05 2013-06-05
PCT/EP2013/072123 WO2014064131A2 (fr) 2012-10-26 2013-10-23 Inhibiteurs de la tyrosine kinase de bruton

Publications (1)

Publication Number Publication Date
HK1210779A1 true HK1210779A1 (en) 2016-05-06

Family

ID=49488574

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15111588.8A HK1210779A1 (en) 2012-10-26 2015-11-25 Inhibitors of brutons tyrosine kinase

Country Status (12)

Country Link
US (1) US20150284394A1 (fr)
JP (1) JP6139690B2 (fr)
KR (1) KR20150060839A (fr)
CN (1) CN104662024B (fr)
AR (1) AR093123A1 (fr)
BR (1) BR112015007513A2 (fr)
CA (1) CA2881070A1 (fr)
HK (1) HK1210779A1 (fr)
MX (1) MX2015002975A (fr)
RU (1) RU2619465C2 (fr)
TW (1) TW201422619A (fr)
WO (1) WO2014064131A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015089327A1 (fr) * 2013-12-11 2015-06-18 Biogen Idec Ma Inc. Composés biaryliques utiles pour le traitement de maladies humaines en oncologie, neurologie et immunologie
SG11201701573QA (en) * 2014-10-06 2017-03-30 Merck Patent Gmbh Heteroaryl compounds as btk inhibitors and uses thereof
KR102519536B1 (ko) 2014-10-24 2023-04-06 브리스톨-마이어스 스큅 컴퍼니 트리시클릭 회전장애이성질체 화합물
PT3209651T (pt) 2014-10-24 2019-12-30 Bristol Myers Squibb Co Derivados de carbazol
KR102686957B1 (ko) * 2016-11-08 2024-07-22 주식회사 대웅제약 신규한 피롤로피리미딘 유도체 및 이를 포함하는 약학적 조성물
JP7476214B2 (ja) 2018-10-15 2024-04-30 バイオジェン・エムエイ・インコーポレイテッド ブルトン型チロシンキナーゼ阻害剤の結晶多形
WO2020234780A1 (fr) * 2019-05-23 2020-11-26 Novartis Ag Méthodes de traitement de l'asthme au moyen d'un inhibiteur de la tyrosine kinase de bruton
US20220411429A1 (en) * 2019-10-30 2022-12-29 Biogen Ma Inc. Condensed pyridazine or pyrimidine as btk inhibitors
MX2022013407A (es) * 2020-04-30 2022-11-14 Beigene Ltd Degradacion de la tirosina cinasa de bruton (btk) mediante conjugacion de inhibidores btk con ligando de ligasa e3 y metodos de uso.
WO2022140246A1 (fr) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Procédés et composés destinés à l'autophagie ciblée
KR102635126B1 (ko) 2021-05-27 2024-02-13 한국과학기술연구원 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 피롤로피리미딘 유도체 및 이들의 용도
CN113735859A (zh) * 2021-08-12 2021-12-03 安徽医科大学 一种激酶抑制剂
CN113583007B (zh) * 2021-08-31 2022-06-10 山东大学 一种吡咯并嘧啶类btk抑制剂及其制备方法与应用
EP4429770A1 (fr) * 2021-11-10 2024-09-18 Biogen MA Inc. Inhibiteurs de btk

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) * 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
PT836605E (pt) * 1995-07-06 2002-07-31 Novartis Ag Pirrolopirimidinas e processos para a sua preparacao
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US7423043B2 (en) * 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
MY159449A (en) * 2005-12-13 2017-01-13 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
EP2043655A2 (fr) * 2006-04-25 2009-04-08 Astex Therapeutics Limited Derives de purine et de deazapurine comme composes pharmaceutiques
JP2009536161A (ja) * 2006-04-25 2009-10-08 アステックス、セラピューティックス、リミテッド 医薬化合物
GB0725103D0 (en) * 2007-12-21 2008-01-30 Glaxo Group Ltd Novel compounds
WO2010036316A1 (fr) * 2008-09-24 2010-04-01 Yangbo Feng Composés d’urée et de carbamate et analogues utilisés comme inhibiteurs de kinase
JP2010170080A (ja) * 2008-12-24 2010-08-05 Sanyo Electric Co Ltd レンズ装置、撮影装置
WO2011029043A1 (fr) * 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Inhibiteurs hétéroaryles de btk
PL2473049T3 (pl) * 2009-09-04 2019-07-31 Biogen Ma Inc. Inhibitory kinazy tyrozynowej brutona

Also Published As

Publication number Publication date
TW201422619A (zh) 2014-06-16
CN104662024A (zh) 2015-05-27
US20150284394A1 (en) 2015-10-08
AR093123A1 (es) 2015-05-20
WO2014064131A3 (fr) 2014-10-16
CN104662024B (zh) 2016-12-07
RU2619465C2 (ru) 2017-05-16
MX2015002975A (es) 2015-06-22
RU2015117949A (ru) 2016-12-20
WO2014064131A2 (fr) 2014-05-01
KR20150060839A (ko) 2015-06-03
BR112015007513A2 (pt) 2017-07-04
JP2015535226A (ja) 2015-12-10
CA2881070A1 (fr) 2014-05-01
JP6139690B2 (ja) 2017-05-31

Similar Documents

Publication Publication Date Title
HK1212689A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
HK1211293A1 (en) Brutons tyrosine kinase inhibitors
IL277951A (en) Pyrimidinyls are tyrosine kinase inhibitors
IL263262B (en) Atr kinase inhibitor compounds, preparations containing them, their uses and methods for their preparation
HK1194381A1 (en) Inhibitors of brutons tyrosine kinase
HK1197060A1 (en) Inhibitors of brutons tyrosine kinase
HK1210779A1 (en) Inhibitors of brutons tyrosine kinase
HK1186186A1 (en) Inhibitors of brutons tyrosine kinase
HK1224173A1 (zh) 布魯頓氏酪氨酸激酶抑制劑和 抑制劑的組合
HK1210461A1 (en) Inhibitors of brutons tyrosine kinase
HK1208803A1 (en) Crystalline forms of a brutons tyrosine kinase inhibitor
HK1210161A1 (en) Heteroaromatic compounds as brutons tyrosine kinase (btk) inhibitors (btk)
HK1208442A1 (en) Substituted pyrrolopyrimidinylamino-benzothiazolones as mknk kinase inhibitors mknk
SI2710005T1 (sl) Zaviralci tirozinske kinaze
HK1200816A1 (en) Inhibitors of brutons tyrosine kinase
HK1206624A1 (en) Brutons tyrosine kinase inhibitors for hematopoietic mobilization
HK1217695A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
EP2988744A4 (fr) Composés aminohétéroaryle à substitution thiazole inhibiteurs de tyrosine kinase splénique
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
HK1215855A1 (zh) 酪氨酸蛋白激酶抑制劑
HK1218416A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
EP2903970A4 (fr) Inhibiteurs substitués de pyrimidinyl kinase
HK1212975A1 (zh) 作為布魯頓氏酪氨酸激酶抑制劑的噻唑衍生物
EP2968995A4 (fr) Inhibiteurs de l'activité kinase lrrk2
HK1218394A1 (zh) 酪氨酸蛋白激酶抑制劑

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211022